SE0010323311
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
News Preview
STOCKHOLM , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
News Preview
STOCKHOLM , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
Leqembi® approved in Mexico
News Preview
STOCKHOLM, Dec. 5, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.
Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
Leqembi® approved in Mexico
News Preview
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.
Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
28.11.2024
BIOA B
LISTED
STO
Leqembi® launched in South Korea
News Preview
STOCKHOLM, Nov. 28, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) o...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2024
BIOA B
LISTED
STO
Leqembi® launched in South Korea
News Preview
STOCKHOLM, Nov. 27, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) o...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
BIOA B
LISTED
STO
CHMP issues positive recommendation for approval of lecanemab in the EU
News Preview
STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recomme...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
BIOA B
LISTED
STO
CHMP issues positive recommendation for approval of lecanemab in the EU
News Preview
STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recomme...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
BrainTransporter™ dramatically improves antibody delivery to the brain
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, e...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
BrainTransporter™ dramatically improves antibody delivery to the brain
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, e...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on Nov...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on Nov...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.11.2024
BIOA B
LISTED
STO
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenan...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
BIOA B
LISTED
STO
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenan...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
BIOA B
LISTED
STO
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give incr...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
BIOA B
LISTED
STO
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give incr...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
BIOA B
LISTED
STO
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid on October 29. Professor Lannfe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
BIOA B
LISTED
STO
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid on October 29. Professor Lannfe...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
BIOA B
LISTED
STO
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
News Preview
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
BIOA B
LISTED
STO
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
News Preview
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
BIOA B
LISTED
STO
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
News Preview
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
BIOA B
LISTED
STO
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
News Preview
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI)...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI)...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new infor...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new infor...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
News Preview
STOCKHOLM, Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 2...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
News Preview
STOCKHOLM, Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 2...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2024
BIOA B
LISTED
STO
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
News Preview
STOCKHOLM, Aug. 14, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi® (lecanemab) for the treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in patients with mild cogni...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2024
BIOA B
LISTED
STO
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
News Preview
STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi® (lecanemab) for the treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in patients with mild cogni...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
